Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The healthcare contract manufacturing market was valued at USD 285.54 Billion in 2025. It is poised to grow at a CAGR of 9.40% during the forecast period of 2026-2035, and reach USD 701.20 Billion by 2035. The market growth is driven by the rising outsourcing by pharmaceutical companies, increasing demand for cost-efficient production, growing biologics pipeline, expansion of manufacturing capacity, and stringent regulatory requirements ensuring quality compliance.
Base Year
Historical Period
Forecast Period
In March 2026, Lonza agreed to divest its Capsules and health ingredients business for USD 2.2 billion, strengthening its position as a pure-play CDMO and reinforcing investment in biologics manufacturing capacity.
In March 2026, Thermo Fisher Scientific expanded its sterile fill-finish manufacturing network, enhancing large-scale production capabilities and addressing increasing outsourcing demand from pharmaceutical companies.
In January 2026, Samsung Biologics secured new long-term manufacturing contracts with global pharma companies, reinforcing its position as a leading large-scale biologics CDMO provider.
Compound Annual Growth Rate
9.4%
Value in USD Billion
2026-2035
*this image is indicative*
The market is expanding consistently, driven by pharmaceutical companies' need to reduce costs, accelerate production timelines, and access specialized manufacturing expertise. From complex medical device assemblies to GMP facility-based pharmaceutical production, contract manufacturers address a broad therapeutic spectrum. Rising healthcare expenditure in emerging markets, Industry 4.0 automation adoption, and increasing regulatory complexity are compelling organizations toward strategic outsourcing, reinforcing sustained global market growth through the forecast period. The market reached a value of approximately USD 285.54 Billion in 2025.
Expansion of Sterile Manufacturing Capabilities Driving the Market Development
Escalating outsourcing demand and increasing preference for integrated drug-device solutions are acting as significant market drivers. For instance, in March 2026, Thermo Fisher expanded its U.S. sterile manufacturing footprint through collaboration with SHL Medical for autoinjector solutions. This development is expected to enhance sterile filling capabilities, improve end-to-end production efficiency, and accelerate contract manufacturing adoption throughout the forecast period.
Key trends shaping the market include rising outsourcing demand, expansion of biologics manufacturing capacity, increasing adoption of advanced technologies, strategic collaborations, and growing emphasis on regulatory compliance and quality standards.
Biologics Capacity Expansion Strengthening the Market Demand
The rising demand for biologics and expanding global manufacturing capacity are serving as major trends in the market. For instance, in January 2026, Samsung Biologics acquired a biologics manufacturing facility in Rockville, strengthening its U.S. presence. This initiative is anticipated to advance biologics manufacturing capabilities, support large-scale production, and reinforce competitive positioning amid growing outsourcing demand in the forecast period.
Market Breakup by Service
Market Breakup by Type
Market Breakup by Class
Market Breakup by Type of Manufacturing
Market Breakup by End User
Market Breakup by Region
Pharmaceutical Companies Expected to Dominate the Market Segment by End User
Pharmaceutical companies dominated the market, capturing over 44% share in the historical period, supported by extensive outsourcing and large-scale production requirements. Their reliance on pharma CMO partnerships enables cost efficiency, scalability, and access to specialized expertise, strengthening supply chain capabilities and ensuring consistent production quality across global pharmaceutical operations and therapeutic segments.
North America led the market with approximately 46% share in the historical period, driven by advanced manufacturing infrastructure and strong industry presence. The region benefits from well-established GMP facility standards, ensuring high-quality production, regulatory compliance, and reliability, which continue to attract pharmaceutical companies seeking efficient and secure manufacturing partnerships globally.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Thermo Fisher Scientific, founded in 2006 and headquartered in Waltham, Massachusetts, USA, is a leading contract development and manufacturing organization. Its portfolio includes biologics production, clinical trial services, and sterile filling solutions supporting complex drug delivery systems. The company enables end-to-end pharmaceutical outsourcing across global markets. In March 2026, Thermo Fisher expanding its U.S. sterile manufacturing footprint through a collaboration with SHL Medical.
Lonza, established in 1897 and headquartered in Basel, Switzerland, is a global CDMO specializing in biologics development and manufacturing. Its portfolio includes cell and gene therapy, mammalian production, and biologics manufacturing platforms supporting large-scale commercial supply. Lonza plays a critical role in enabling innovative therapies through advanced manufacturing expertise.
Celestica Inc., founded in 1994 and headquartered in Toronto, Canada, provides advanced manufacturing and supply chain solutions. Its healthcare portfolio includes medical device production, precision electronics, and outsourcing strategy support for complex systems. The company enables scalable manufacturing capabilities for global healthcare and life sciences customers.
Integer Holdings Corporation, established in 1970 and headquartered in Plano, Texas, USA, is a leading medical device outsourcing manufacturer. Its portfolio includes implantable devices, components, and quality agreement-driven manufacturing solutions ensuring compliance and reliability. The company supports medical device firms with end-to-end production and engineering services.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market are Nordson Corporation, Sanmina Corporation, Phillips-Medisize - a Molex Company, Catalent, Inc, Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Cambrex Corporation, and Recifarm.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service |
|
| Breakup by Type |
|
|
Breakup by Class |
|
| Breakup by Type of Manufacturing |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share